The International TILs Working Group has proposed an sTIL cutoff of 50% of define lymphocyte-predominant breast cancer, although their guidelines acknowledge that the prognostic and predictive value of sTIL is most evident in TNBC and HER2-positive breast cancer [21]. The gene discussed is ERBB2; the disease is breast carcinoma.